<DOC>
	<DOCNO>NCT01644890</DOCNO>
	<brief_summary>To verify non-inferiority NK105 , paclitaxel-incorporating micellar nanoparticle , paclitaxel term progression-free survival patient metastatic recurrent breast cancer .</brief_summary>
	<brief_title>A Phase III Study NK105 Patients With Breast Cancer</brief_title>
	<detailed_description>This study randomize , open-label , multi-national phase III study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent patient sign . Histologically confirm metastatic recurrent adenocarcinoma breast . Aged 20 74 time inform consent . Prior systemic chemotherapy taxane anticancer drug metastatic recurrent breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NK105 , Paclitaxel , Breast cancer , Micelle</keyword>
</DOC>